분자유전학실험실 (단국대학교 분자생물학과)

 이성욱 ( 2009-12-04 13:41:21 , Hit : 4265
 RNA Silencer Shows Promise for Hepatitis C

By Martin Enserink
ScienceNOW Daily News
3 December 2009

Researchers have come up with a completely new way to thwart hepatitis C: Go after the host, not the virus. Genetically silencing a small piece of RNA in chimpanzees effectively suppresses the hepatitis C virus (HCV), a new study shows--and the virus appears unable to become resistant to the treatment. But experts caution that the approach needs to be scrutinized carefully for side effects.
New drugs against HCV are badly needed. More than 170 million people worldwide have contracted the virus, which is transmitted primarily via injection drug use and through the transfusion of blood and blood products. The virus slowly scars the liver, leading to liver failure and sometimes liver cancer.

The standard treatment, a combination of two antiviral drugs called pegylated interferon-α and ribavirin, takes 24 to 48 weeks, can cause a range of side effects, and fully eliminates the virus in only 50% to 80% of patients. Pharmaceutical companies are developing several new antiviral drugs, including so-called polymerase and protease inhibitors, but the virus can become resistant to these quite easily.

The new study builds on a discovery published in Science in 2005 by Stanford University virologist Peter Sarnow and his colleagues. The team found that HCV depends on a tiny piece of RNA that is produced by the host and involved in the regulation of hundreds of genes, many of them related to cholesterol and lipid synthesis. Exactly what the "micro-RNA" snippet, called miR-122, does for the virus is still unclear; it may boost its replication or stability, or it may somehow protect it from the immune system.

Sarnow's work led Santaris Pharma, a biotech in Hørsholm, Denmark, to develop a candidate drug that can block miR-122. The compound, called SPC3649, is a short piece of artificial DNA that blocks miR-122 in mice and in green African monkeys. But those species don't get hepatitis C.

In the new paper, published online today in Science, the researchers tested the drug in four chimpanzees, the only nonhuman animal that gets HCV. The chimps had been infected with HCV in previous studies at the Southwest Foundation for Biomedical Research in San Antonio, Texas. Two of them were injected weekly with a low dose of SPC3649 for 12 weeks, the other two with a high dose.

The high dose reduces the amount of virus in the chimps' liver by more than 99.5%, the researchers found. (With the lower dose, one of the animals had a smaller decline, whereas the other responded poorly.) Needle biopsies from their livers, taken while the animals were anaesthetized and examined under a microscope, showed that the treatment resulted in more healthy-looking tissue. Throughout the study, there were no signs of resistance; the virus didn't rebound as the weeks passed--as often happens with other drugs--and there were no genetic changes in the place where the virus binds to miR-122. Targeting a host micro-RNA may be a smarter strategy than targeting a viral protein, says Santaris's Vice President and Chief Scientific Officer Henrik Ørum, because the virus cannot modify the host the way it can its own genes.

"It's a very nice proof of principle," says virologist Ben Berkhout of the Academic Medical Center in Amsterdam; the reduction in viral load is "very robust," he adds. Stanley Lemon of the University of Texas Medical Branch in Galveston, a co-author on Sarnow's 2005 paper, agrees. But he warns that with a drug that regulates the expression of so many genes--including some cancer-related ones--there are serious concerns about side effects. None were observed in the study, but still, "if I were leading a pharmaceutical company looking where to invest my money, I might be worried about that," says Lemon.

Ørum agrees that there is a risk, but he points out that hepatitis C is a life-threatening disease and that the hope is that patients would only have to take SPC3649 for a limited time, presumably with another drug, before they clear the virus. Santaris has completed a phase I study of the drug--in which safety is tested in healthy human volunteers--but the results have not been published.

Meanwhile, it's unclear whether the same strategy can have any use in other infections, says virologist Bryan Cullen of Duke University Medical Center in Durham, North Carolina, because currently no other virus is known to be dependent on a human microRNA. "I keep hearing rumors about other papers out there," says Cullen. "But for the moment, this is a unique case."


Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection
Robert E. Lanford,1,* Elisabeth S. Hildebrandt-Eriksen,2,* Andreas Petri,2,* Robert Persson,2 Morten Lindow,2 Martin E. Munk,2 Sakari Kauppinen,2,3,* Henrik Ørum2,

The liver-expressed microRNA-122 (miR-122) is essential for hepatitis C virus (HCV) RNA accumulation in cultured liver cells, but its potential as a target for antiviral intervention has not been assessed. Here, we show that treatment of chronically infected chimpanzees with a locked nucleic acid (LNA)-modified oligonucleotide (SPC3649) complementary to miR-122 leads to long-lasting suppression of HCV viremia with no evidence for viral resistance or side effects in the treated animals. Furthermore, transcriptome and histological analyses of liver biopsies demonstrated derepression of target mRNAs with miR-122 seed sites, down-regulation of interferon-regulated genes (IRGs), and improvement of HCV-induced liver pathology. The prolonged virological response to SPC3649 treatment without HCV rebound holds promise of a new antiviral therapy with a high barrier to resistance.

1 Department of Virology and Immunology and Southwest National Primate Research Center, Southwest Foundation for Biomedical Research, San Antonio, TX 78227, USA.
2 Santaris Pharma, Kogle Allé 6, DK-2970 Hørsholm, Denmark.
3 Copenhagen Institute of Technology, Aalborg University, Lautrupvang 15, DK-2750 Ballerup, Denmark.
* These authors contributed equally to this work.

To whom correspondence should be addressed. E-mail: hoe@santaris.com

Received for publication 24 June 2009. Accepted for publication 30 October 2009.

907   패혈증의 사망원인이 되는 Histones  이성욱 2009/11/30 6425
906   알츠하이머의 독성 아밀로이드베타 단백질의 정상적 기능발견  이성욱 2009/11/30 5909
905   세포의 새로운 자기방어 메커니즘: 의도적인 단백질 번역오류  이성욱 2009/11/30 5065
  RNA Silencer Shows Promise for Hepatitis C  이성욱 2009/12/04 4265
903   박테리아의 면역시스템 규명  이성욱 2009/12/04 4791
902   miRNA를 침묵시켜 C형간염을 치료  이성욱 2009/12/07 4701
901   왜 어떤 원숭이는 에이즈에 걸리지 않는가?  이성욱 2009/12/09 5266
900   겸상적혈구 빈혈증 치료의 새로운 접근방법: BCL11A 유전자를 불활성화  관리자 2009/12/10 5810
899   약물을 사용하지 않고 공포의 기억을 지운다  이성욱 2009/12/11 4586
898   microRNA Discovery Might Help ALS Patients  이성욱 2009/12/14 4783
897   단백질 합성과정에서 알라닌의 오역(mistranslation)이 빈발하는 이유와 그 해결방법  이성욱 2009/12/14 5632
896   유전자 연구를 통해 발견한 단일 이동으로 이루어진 아시아 인구  이성욱 2009/12/15 4723
895   Adult Cells Turned Stem Cell iPS cells were recently shown to rescue vision in blind rats  이성욱 2009/12/15 2571
894   tRNA 합성효소의 이중기능(dual function)에 대한 미스터리 해명  이성욱 2009/12/18 6412
893   단백질 합성의 온-오프 스위치를 개발  이성욱 2009/12/18 5308
892   좀더 간단한 유도만능줄기세포 기술개발  이성욱 2009/12/18 4551
891   신장암에서 유효성을 보인 압타머  이성욱 2009/12/22 6029
890   Hepatitis C Drug Targets RNA  이성욱 2009/12/23 3971
889   빠르고, 값싼 DNA 시퀀싱 방법 개발  이성욱 2009/12/25 5177
888   줄기 세포에서 E2F단백질의 기능 전환  이성욱 2009/12/25 5861

[이전 10개] [1]..[11][12][13][14][15][16][17][18] 19 [20]..[64] [다음 10개]

Copyright 1999-2024 Zeroboard / skin by ROBIN